3D-QSAR Studies on Protein Phosphatase 2A Inhibitors as Anti-cancer Agents

Authors

  • Zofina Patel Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Gujarat
  • M. N Noolvi Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Gujarat
  • Uttam A More Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Gujarat

Abstract

The tremendous efforts by researcher indicates that cantharidin, nor cantharidin and their analogues shows anti-cancer activity due to their inhibition of cancer cell lines such as HT29, SW480, MCF-7, A2780, H460, A431, DU145 and L1210. The anti-cancer activities of cantharidin, nor cantharidin and their analogues involve the inhibition of serine/threonine protein phosphatises (PPs) activity. In this study, three-dimensional quantitative structure activity relationship (3D-QSAR) like comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) were performed on a set of cantharid in and nor cantharidin analogues. According to 3D-QSAR studies, The CoMFA model with steric and electrostatic field exhibited q2=0.547, r2=0.784; CoMSIA model displayed q2=0.560, r2=0.871; with a standard error of estimate (SEE) of 0.3855 and 0.3000 and number of component (NOC) 3 and 4 respectively. The developed validated 3D-QSAR models can be used to design and new anti-cancer derivatives.

 

Keywords: Cantharidin, protein phosphatase inhibitors, anti-cancer, CoMFA, CoMSIA

QSAR-CoMFA

Downloads

Published

2019-01-17

Issue

Vol. 5 No. 3 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.